Correction: Watanabe et al. Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. Livers 2023, 3, 562–568
Error in Table 4
Reference
- Watanabe, A.; Horigome, R.; Nakatsuka, Y.; Terai, S. Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. Livers 2023, 3, 562–568. [Google Scholar] [CrossRef]
Variables | Before | After | p Value |
---|---|---|---|
Weight (kg) | 68.3 ± 14.2 | 68.9 ± 14.1 | <0.05 |
BMI (kg/m2) | 25.4 ± 4.2 | 25.7 ± 4.1 | <0.05 |
AST (IU/L) | 36.1 ± 32.1 | 27.8 ± 17.0 | 0.005 |
ALT (IU/L) | 43.7 ± 43.8 | 24.0 ± 13.8 | <0.001 |
γ-GPT (IU/L) | 93.8 ± 210.2 | 44.3 ± 129.3 | <0.001 |
Platelet (104/μL) | 24.6 ± 7.2 | 26.9 ± 8.6 | <0.001 |
M2BPGi | 0.9 ± 0.7 | 0.7 ± 0.5 | <0.05 |
Triglyceride (mg/dL) | 234.6 ± 126.3 | 126.7 ± 68.4 | <0.001 |
HDL-C (mg/dL) | 52.6 ± 12.9 | 55.7 ± 11.6 | 0.001 |
LDL-C (mg/dL) | 118.4 ± 35.2 | 111.9 ± 28.0 | 0.06 |
Cre (mg/dL) | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.57 |
eGFR (mL/min/1.73 m2) | 73.0 ± 15.2 | 73.1 ± 15.5 | 0.70 |
Glucose (mg/dL) | 138.7 ± 42.1 | 130.4 ± 38.1 | 0.15 |
HbA1c (%) | 6.5 ± 1.0 | 6.4 ± 1.0 | 0.87 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Watanabe, A.; Horigome, R.; Nakatsuka, Y.; Terai, S. Correction: Watanabe et al. Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. Livers 2023, 3, 562–568. Livers 2025, 5, 10. https://doi.org/10.3390/livers5010010
Watanabe A, Horigome R, Nakatsuka Y, Terai S. Correction: Watanabe et al. Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. Livers 2023, 3, 562–568. Livers. 2025; 5(1):10. https://doi.org/10.3390/livers5010010
Chicago/Turabian StyleWatanabe, Azuma, Ryoko Horigome, Yumiko Nakatsuka, and Shuji Terai. 2025. "Correction: Watanabe et al. Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. Livers 2023, 3, 562–568" Livers 5, no. 1: 10. https://doi.org/10.3390/livers5010010
APA StyleWatanabe, A., Horigome, R., Nakatsuka, Y., & Terai, S. (2025). Correction: Watanabe et al. Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. Livers 2023, 3, 562–568. Livers, 5(1), 10. https://doi.org/10.3390/livers5010010